title: Cellular differentiation in ovarian sex-cord-stromal and germ-cell tumors studied with antibodies to intermediate-filament proteins.
abstract: Seventy ovarian sex-cord-stromal and germ-cell tumors were immunohistochemically studied for the presence of intermediate-filament proteins of different types used as markers for cellular differentiation. Cells of ovarian granulosa-cell tumors constantly expressed vimentin and appeared to lack cytokeratin. Two tumors previously classified as granulosa-cell tumors were reclassified as poorly differentiated "common" epithelial tumors based on their cytokeratin positivity, vimentin negativity, and morphologic features. Dysgerminomas and Leydig-cell tumors showed only vimentin positivity. Tubular structures in androblastomas, which are considered to represent Sertoli-cell differentiation, were cytokeratin positive, and thus differed from the majority of normal Sertoli cells that are known to express vimentin and not cytokeratin. Embryonal carcinomas, choriocarcinomas, and endodermal sinus tumors showed cytokeratin positivity in the neoplastic cells whereas vimentin was observed in the stromal cells. In immature teratomas, epithelial differentiation was demonstrated with cytokeratin antibodies, and neural and glial differentiation was also frequently demonstrated by immunostaining with antibodies to neurofilaments and glial fibrillary acidic protein. The results show that antibodies to intermediate filaments can be used in the differential diagnosis between ovarian epithelial and nonepithelial tumors, and they provide a very accurate additional method to characterize the cellular differentiation of ovarian neoplasms.
mesh_terms: D000818:Animals; D000906:Antibodies; D002471:Cell Transformation, Neoplastic / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D002822:Choriocarcinoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D005260:Female; D005350:Fibroma / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006106:Granulosa Cell Tumor / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006651:Histocytochemistry; D006801:Humans; D007158:Immunologic Techniques; D007381:Intermediate Filament Proteins / Q000276:immunology*; D007984:Leydig Cell Tumor / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009373:Neoplasms, Germ Cell and Embryonal / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D011247:Pregnancy; D011817:Rabbits; D012707:Sertoli Cell Tumor / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013724:Teratoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013798:Thecoma / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D000906:Antibodies; D007381:Intermediate Filament Proteins